Aprea Therapeutics Inc (APRE) Stock Price, Quote & News

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid t...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 948 4119

Website: aprea.com

Address:

3805 Old Easton Road, Doylestown, United States

Bulltrader988 Apr. 21 at 4:37 PM

$APRE "....today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago..." 👃👀 https://www.stocktitan.net/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-0athjb0e4g94.html

0 · Reply

erb71 Apr. 21 at 4:28 PM

$APRE (not advice, just pattern probabilities)

1 · Reply

ArcherMagnum Apr. 19 at 2:13 AM

$APRE Following the clinical data and the capital raise, analysts from firms like Wedbush have reaffirmed "Outperform" ratings, with some maintaining price targets in the $7.00 range.

0 · Reply

FillSniper42 Apr. 17 at 7:59 PM

ABTS stock will 5X from here back to $5-$10+ cheapest mining play on the market - Bottomed out near all time low at 1.30 and was 10+ a few months ago - Only droped because of the crypto selloff..now with crypto reversing it will go back to new highs - 2M float so can have explosive moves at any time and they have real bitcoin mining operations across the US. $SNYR $AMS $APRE $

0 · Reply

erb71 Apr. 17 at 2:42 PM

$APRE ~60%+ since the post below.

0 · Reply

MarketMasterMind Apr. 17 at 2:02 PM

$APRE loaded 🤑Ⓜ️

0 · Reply

CarlosNosca Apr. 14 at 5:36 PM

$APRE out for a small profit. made good profit in the past, but at the moment I think that this stock it's quite challenging... good luck everybody.

0 · Reply

erb71 Apr. 13 at 3:07 PM

$APRE may be resting before besting.

0 · Reply

boxeodecuba Apr. 11 at 9:34 AM

$APRE good news ,,next week

0 · Reply

erb71 Apr. 10 at 4:37 PM

$APRE Weak hands or shorts have likely been selling. Either way, it may be strengthening the holder base.

0 · Reply

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Apr 1, 2026, 8:30 AM EDT - 24 days ago

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Mar 30, 2026, 8:01 AM EDT - 26 days ago

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Mar 30, 2026, 8:00 AM EDT - 26 days ago

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Mar 16, 2026, 8:00 AM EDT - 5 weeks ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Feb 26, 2026, 8:40 AM EST - 2 months ago

Aprea Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 2:02 PM EST - 2 months ago

Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Feb 18, 2026, 8:00 AM EST - 2 months ago

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Feb 17, 2026, 8:00 AM EST - 2 months ago

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 12, 2026, 8:30 AM EST - 2 months ago

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Feb 4, 2026, 8:30 AM EST - 2 months ago

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Jan 29, 2026, 8:27 AM EST - 3 months ago

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Jan 29, 2026, 8:25 AM EST - 3 months ago

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 18, 2025, 8:30 AM EST - 4 months ago

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

Dec 9, 2025, 8:30 AM EST - 4 months ago

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Nov 12, 2025, 8:30 AM EST - 5 months ago

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Oct 24, 2025, 8:30 AM EDT - 6 months ago

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Oct 15, 2025, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Oct 14, 2025, 8:00 AM EDT - 6 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Sep 9, 2025, 3:30 PM EDT - 8 months ago

Aprea Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:30 AM EDT - 8 months ago

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

Jun 25, 2025, 9:00 AM EDT - 10 months ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

May 14, 2025, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Feb 5, 2025, 8:00 AM EST - 1 year ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Dec 11, 2024, 8:30 AM EST - 1 year ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Sep 9, 2024, 5:15 PM EDT - 1 year ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 24, 2024, 9:00 AM EDT - 1 year ago

Aprea Therapeutics Transcript: Study Update

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 17, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

May 28, 2024, 8:45 AM EDT - 2 years ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 14, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:01 PM EDT - 2 years ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 9:15 AM EDT - 2 years ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Apr 10, 2024, 12:00 PM EDT - 2 years ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Mar 26, 2024, 7:45 AM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 7:48 AM EDT - 2 years ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:29 AM EDT - 2 years ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 5, 2024, 4:45 PM EST - 2 years ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Feb 6, 2024, 8:01 AM EST - 2 years ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Jan 30, 2024, 8:00 AM EST - 2 years ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Oct 31, 2023, 11:00 AM EDT - 2 years ago

Aprea Therapeutics Transcript: Study Update

Bulltrader988 Apr. 21 at 4:37 PM

0 · Reply

erb71 Apr. 21 at 4:28 PM

$APRE (not advice, just pattern probabilities)

1 · Reply

ArcherMagnum Apr. 19 at 2:13 AM

$APRE Following the clinical data and the capital raise, analysts from firms like Wedbush have reaffirmed "Outperform" ratings, with some maintaining price targets in the $7.00 range.

0 · Reply

FillSniper42 Apr. 17 at 7:59 PM

0 · Reply

erb71 Apr. 17 at 2:42 PM

$APRE ~60%+ since the post below.

0 · Reply

MarketMasterMind Apr. 17 at 2:02 PM

$APRE loaded 🤑Ⓜ️

0 · Reply

CarlosNosca Apr. 14 at 5:36 PM

$APRE out for a small profit. made good profit in the past, but at the moment I think that this stock it's quite challenging... good luck everybody.

0 · Reply

erb71 Apr. 13 at 3:07 PM

$APRE may be resting before besting.

0 · Reply

boxeodecuba Apr. 11 at 9:34 AM

$APRE good news ,,next week

0 · Reply

erb71 Apr. 10 at 4:37 PM

$APRE Weak hands or shorts have likely been selling. Either way, it may be strengthening the holder base.

0 · Reply

vcaelum Apr. 10 at 3:37 PM

$APRE in 0.88, looking for $1+, HARD SL 0.8 . Let me get my wins pls

0 · Reply

YungnredE Apr. 10 at 2:23 PM

$APRE News came out a week ago... price just now reacts off of it and it's the same volume it's been having since last week... market is so corrupt.

0 · Reply

Samuelstark Apr. 10 at 2:16 PM

$APRE 👀

0 · Reply

YungnredE Apr. 10 at 2:11 PM

$APRE it really took this long for the news to hit wow...

0 · Reply

erb71 Apr. 10 at 2:10 PM

$APRE

0 · Reply

SannieVerraderlijk Apr. 9 at 5:49 PM

$APRE Hi, wen $ZNTL sympathy pump?

0 · Reply

NasdaqPulse Apr. 9 at 4:04 PM

$COP Earnings Alert 👉Click to view @NasdaqPulse for timely updates amid the volatility. ConocoPhillips ($COP) set to report April 30th – and the numbers aren’t looking great. Analysts are expecting a 22% YoY decline in EPS. 🔻 What’s driving the dip? Lower oil prices? Production slowdown? Market uncertainty? This could be a big miss or an opportunity depending on how it plays out. If you're holding $COP, this report could shake things up. What will the market do with this info? If they miss, could we see further downside, or will the market brush it off as priced in? The clock is ticking… Keep an eye on $COP, and also watch $APRE if you're looking at energy sector moves.

0 · Reply

makny Apr. 8 at 1:53 PM

$APRE total garbage, market is garbage after a long time but this is hardly moving.

0 · Reply

topstockalerts Apr. 7 at 8:44 PM

After Hours Top Gainers $QNCX $IRIX $YXT $GLXG $APRE

0 · Reply

Bulltrader988 Apr. 7 at 8:33 PM

$APRE Next 13G filled today: Squadron Master Fund LP 1,271,081 shares = 9.9 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1781983/000205070926000012/xslSCHEDULE_13G_X02/primary_doc.xml

0 · Reply

focafoca99 Apr. 6 at 6:34 PM

$APRE Frazier Life Sciences bringing in Christian Schade as senior advisor.

0 · Reply

TezBunny Apr. 4 at 11:28 AM

$APRE Lets RS this sucker and smash this thing down hahahahahahahaha😂🤣

0 · Reply

Market Cap	10.13M
Revenue (ttm)	290,000.00
Net Income (ttm)	-12.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,344.83%
Debt to Equity Ratio	0.00

Volume	40,600
Avg Vol	505,822
Day's Range	N/A - N/A
Shares Out	11.45M
Stochastic %K	39%
Beta	1.47
Analysts	Strong Sell
Price Target	$4.40